{
    "nctId": "NCT00255463",
    "briefTitle": "Phase II Neoadjuvant ER+/PgR + Arimidex +/- Iressa Study",
    "officialTitle": "Phase II, Placebo Controlled, Parallel Group, Double Blind, Randomised, Multicentre Trial Comparing the Anastrozole (Arimidex\u00ae) Placebo Combination to the Anastrozole - ZD1839 (Iressa\u2122) Combination as Neoadjuvant Treatment in Postmenopausal Women With Stage I-IIIB Breast Cancer and Oestrogen Receptor (ER) and/or Progesterone (PgR) Positive Tumours",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 185,
    "primaryOutcomeMeasure": "To determine and compare changes in proliferation marker at 16 weeks in the treatment groups",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Measurable (stage I-IIIB) non meta static non inflammatory breast cancer\n* Patients must post menopausal women who in the opinion of investigator would be likely to benefit from endocrine therapy. Postmenopausal patients are defined as:\n* Natural menopause with last menses \\> 1 year ago,\n* Radiation induced oophorectomy with last menses \\> 1 year ago,\n* Serum FSH and LH levels clearly in the postmenopausal range for the institution.\n* Bilateral oophorectomy\n\nExclusion Criteria:\n\n* Other current or previous (to last 5 years) malignancies, other metastases, abnormal blood chemistry, lung/ heart/kidney/liver abnormalities,\n* Hormonal treatment within the last 2 weeks, previous hormonal treatment for invasive cancer",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}